Medicinova Inc (MNOV): Insider Trading, Congress Trades & Research | Tormere

MNOV

$1.42-1.39%visit website

MEDICINOVA INC

Market Cap

$70M

Live price × SEC shares (Aug 11, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.71

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

75.9

TTM to Jun 2026 · revenue

P/B

1.9

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	123	152	187	458	920
Research & development	1,500	1,400	1,200	900	5,000
Total operating expenses	3,504	3,244	3,023	3,000	12,771
Operating income	(3,381)	(3,092)	(2,836)	(2,541)	(11,850)
Net income	(3,050)	(2,802)	(2,586)	(2,314)	(10,753)
EPS (basic) ($)	(0.06)		(0.05)	(0.05)	(0.21)
EPS (diluted) ($)	(0.06)		(0.05)	(0.05)	(0.21)
Weighted avg. shares (basic)	49,046		49,221	49,221
Weighted avg. shares (diluted)	49,046		49,221	49,221

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

3D Investment Partners Pte. Ltd. · 2026-09-29

Analyst Consensus

Strong Buy

10 analysts

Velocity Score

23.98x

Avg Daily Selling (90d)

7,111 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

1

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-25	2026-09-29	3D Investment Partners Pte. Ltd.	Formerly 10% Owner	Sale	640.0K	$2.70	$1.73M	4.86M	View

Recent News

Medicinova Stock Price Forecast. Should You Buy MNOV?

StockInvest.us · 2026-10-30

MediciNova(MNOV) Stock Options Chain | Quotes & News

Moomoo · 2026-10-24

MediciNova CEO Provides Shareholder Update

Yahoo · 2026-10-12

Two cholesterol measures improved significantly, but the trial missed its primary endpoints.

Stock Titan · 2026-10-12

MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

Benzinga · 2026-10-12

MediciNova to Participate in the Maxim Growth Summit

Yahoo · 2026-10-06

MediciNova (NasdaqGM:MNOV) Stock Forecast & Analyst Predictions

Simply Wall St · 2026-09-29

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

Yahoo Finance · 2026-09-28

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

Yahoo Finance · 2026-09-28

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Yahoo Finance · 2026-09-28

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Yahoo Finance · 2026-09-28

Why Is MediciNova Stock Tumbling Today? - MediciNova (NASDAQ:MNOV)

Benzinga · 2026-09-28

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Yahoo Finance · 2026-09-24

MediciNova to Participate in Two Investor Conferences in September

Yahoo Finance · 2026-09-08

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Yahoo Finance · 2026-05-16

Informational purposes only, not investment advice.

Corporate Events (8-K)

6 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Sep 28, 2026 accepted 4:05 PM ET	1.01Material agreement	Document SEC ↗
Sep 2, 2026 accepted 7:30 AM ET	1.02Agreement terminated	Document SEC ↗
Aug 19, 2026 accepted 7:30 AM ET	5.02Officer / director change	Document SEC ↗
Jun 24, 2026 accepted 4:38 PM ET	5.07Shareholder vote	Document SEC ↗
Feb 20, 2026 accepted 6:25 AM ET	2.02Earnings release	Document SEC ↗
Dec 30, 2025 accepted 7:53 AM ET	1.01Material agreement	Document SEC ↗
Aug 1, 2025 accepted 7:49 PM ET	1.01Material agreement	Document SEC ↗
Jun 18, 2025 accepted 4:30 PM ET	5.07Shareholder vote	Document SEC ↗
Mar 11, 2025 accepted 4:45 PM ET	7.01Reg FD disclosure	Document SEC ↗